<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Biochem Behav</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Biochem Behav</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacology, biochemistry, and behavior</journal-title></journal-title-group><issn pub-type="ppub">0091-3057</issn><issn pub-type="epub">1873-5177</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10117180</article-id><article-id pub-id-type="pmcid-ver">PMC10117180.1</article-id><article-id pub-id-type="pmcaid">10117180</article-id><article-id pub-id-type="pmcaiid">10117180</article-id><article-id pub-id-type="manuscript-id">NIHMS1879817</article-id><article-id pub-id-type="pmid">36244527</article-id><article-id pub-id-type="doi">10.1016/j.pbb.2022.173482</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1879817</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1879817</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Castillo</surname><given-names initials="F">F.</given-names></name><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="JD">J.D.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luba</surname><given-names initials="RR">R.R.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mogali</surname><given-names initials="S">S.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Foltin</surname><given-names initials="RW">R.W.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Evans</surname><given-names initials="SM">S.M.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Comer</surname><given-names initials="SD">S.D.</given-names></name></contrib><aff id="A1">Division on Substance Use Disorders, New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 66, New York, NY 10032, United States of America</aff></contrib-group><author-notes><corresp id="CR1"><label>*</label>Corresponding author at: The New York State Psychiatric Institute &amp; Vagelos College of Physicians &amp; Surgeons of Columbia University, 1051 Riverside Drive, Unit 66, New York, NY 10032, United States of America. <email>felipe.castillo@nyspi.columbia.edu</email> (F. Castillo).</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>10</month><year>2022</year></pub-date><volume>221</volume><issue-id pub-id-type="pmc-issue-id">433865</issue-id><fpage>173482</fpage><lpage>173482</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>04</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 11:25:31.053"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1879817.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">People who have co-occurring Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) carry a higher risk of adverse outcomes, including drug overdose. Early clinical and preclinical studies suggested that gabapentin may be effective in treating both disorders. The present study was designed to assess the effects of gabapentin on the subjective and physiological effects of oxycodone (OXY) and alcohol (ALC), alone and in combination.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">During an 8-week, inpatient, within-subject, randomized, double-blind, placebo-controlled crossover study, non-treatment seeking participants (<italic toggle="yes">N</italic> = 13; 12 M/1F; 44.1 &#177; 3 years of age) with OUD and AUD were maintained on oral morphine (120 mg daily). Under gabapentin (1800 mg/day) and placebo (0 mg/day) maintenance, participants completed nine separate test sessions (three sessions per week) during which they received an oral solution containing 0, 15, or 30 mg/70 kg OXY in combination with 0, 0.5, or 0.75 g/kg ALC. During test sessions, subjective effects and physiological responses were assessed repeatedly on 100-mm visual analog scales (VAS). The primary outcome variable was the VAS rating of drug liking after receiving the drug challenge.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Alcohol alone (but not oxycodone alone) produced dose-related increases in several positive subjective responses, including drug liking. Gabapentin significantly increased drug liking when given in combination with ALC and OXY + ALC (<italic toggle="yes">p</italic> &lt; 0.05). Gabapentin did not clinically compromise respiration or other vital functions.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">Gabapentin may increase the abuse liability of ALC and OXY + ALC in those with co-occurring OUD and AUD.</p></sec></abstract><kwd-group><kwd>Alcohol</kwd><kwd>Opioids</kwd><kwd>Gabapentin</kwd><kwd>Behavioral pharmacology - humans</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>